GlobeNewswire Inc.··NaArvinas to Showcase ARV-102 Parkinson's Data at Major Neurology Conference
Arvinas will present Phase 1 data for ARV-102, a PROTAC LRRK2 degrader, at AD/PD 2026 conference in Copenhagen, with Phase 1b trial planned for progressive supranuclear palsy.
ARVNPhase 1 clinical trialParkinson's disease